Item 8.01 Other Events.

Aptinyx Inc. (Nasdaq: APTX) (the "Company") has temporarily paused the initiation of its Phase 2b study of the 150 mg dose of NYX-783 in patients with post-traumatic stress disorder ("PTSD"). The Company's ongoing Phase 2b study of the 50 mg dose of NYX-783 in PTSD is continuing as planned and will be supported by clinical study sites originally slated for the 150 mg study.





Forward-Looking Statements

Statements contained in this report regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, therapeutic effects of the company's product candidates, and expectations regarding the implementation of its current clinical studies. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; regulatory developments in the United States and foreign countries; as well as those risks and uncertainties set forth in the company's most recent annual report on Form 10-K and in its other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

© Edgar Online, source Glimpses